Browse Negotiations Image Banner

Indication:

Triple-negative breast cancer (mTNBC), unresectable locally advanced or metastatic, in adult patients who have received two or more prior therapies, at least one of them for metastatic disease

Indication:

Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer in adult patients, whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.

Indication:

Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD-L1 (CPS ? 10) as determined by a validated test (in combination with chemotherapy)

Indication:

Persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ? 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients

Indication:

Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients

Indication:

Multiple myeloma, relapsed or refractory, in patients who have received 1 to 3 prior lines of therapy (in combination with carfilzomib and dexamethasone)

Indication:

Multiple myeloma, relapsed and refractory, in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. (in combination with pomalidomide and dexamethasone)

Indication:

Severe Primary Insulin-like Growth Factor-1 Deficiency

Indication:

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL)

Indication:

Lambert-Eaton Myasthenic Syndrome (LEMS)